

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application Number	09/826,609
Filing Date	April 5, 2001
First Named Inventor	Roberts, Bruce
Group Art Unit	1632
Examiner Name	Anjum I Rishi
Attorney Docket Number	GA0150C

(use as many sheets as necessary)

Sheet 1 of 3

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
KAL	1	US-5,695,937	12-09-1997	JHU	
	2	US-			
	3	US-			
	4	US-			
	5	US-			
	6	US-			
	7	US-			
	8	US-			
	9	US-			
	10	US-			
	11	US-			
	12	US-			
	13	US-			
	14	US-			
	15	US-			
	16	US-			
	17	US-			
	18	US-			
	19	US-			
	20	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
KAL	21	WO 95/04542	02-16-95	Cytel Corporation		
KAL	22	WO 96/18409	06-20-96	Scripps Research Inst.		
	23					
	24					
	25					
	26					
	27					
	28					
	29					

Examiner  
Signature

Karen A. Canella

Date  
Considered

9/3/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUN 18 2002

RECEIVED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number	09/826.609
Filing Date	April 5, 2001
First Named Inventor	Roberts, Bruce
Group Art Unit	1632
Examiner Name	Anjum I Rishi
Attorney Docket Number	GA0150C

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAL	30	ABDEL-WAHAB, Z. et al., "Human Dendritic Cells with either Melanoma Tumor Cell Lysates or the gp100 Peptide (280-288), Induce Pairs of T-Cell Cultures with Similar Phenotype and Lytic Activity", Cellular Immunology, 1998, 186:63-74	
	31	ADAMS, M.D. et al., "Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project", Science, June 1991, 252:1651-1656	
	32	COULIE, P.G., "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?", Molecular Medicine Today, June 1997, 261-268	
	33	DEL GIUDICE, G., "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia, 1994, 50:1061-1066	
	34	DILLMAN, R.O. et al., "Establishing In Vitro Cultures of Autologous Tumor Cells for Use in Active Specific Immunotherapy", Journal of Immunotherapy, April 1993, 14(1):65-69	
	35	HEDRICK, S.M. et al., "Isolation of cDNA clones encoding T cell-specific membrane-associated proteins", Nature, March 1984, 308(8):149-152	
	36	KOCHER, O. et al., "Identification of a Novel Gene, Selectively Up-Regulated in Human Carcinomas, Using the Differential Display Technique", Clinical Cancer Research, October 1995, 1209-1215	
	37	LIANG and PARDEE, "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction", Science, August 1992, 257:967-971	
	38	LU, J. et al., "Gene Expression Changes Associated with Chemically Induced Rat Mammary Carcinogenesis", Molecular Carcinogenesis, 1997, 20:204-215	
	39	MILLER and VILE, "Targeted vectors for gene therapy", The FASEB Journal, February 1995, 9:190-199	
✓	40	NINOMIYA-TSUJI, J. et al., "Cloning of a human cDNA encoding a CDC2-related kinase by complementation of a budding yeast cdc28 mutation", Proc. National Academy of Science, October 1991, 88:9006-9010	

Examiner  
Signature

Karen A. Gamella

Date  
Considered

9/3/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
JUN 18 2002

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

**Complete if Known**

Application Number	09/826,609
Filing Date	April 5, 2001
First Named Inventor	Roberts, Bruce
Group Art Unit	1632
Examiner Name	Anjum I. Rishi
Attorney Docket Number	GA0150C

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KA ✓	41	POLYAK, K. et al., "A model for p53-induced apoptosis", Letters to Nature, September 1997, 389:300-305	
	42	SETTE, A. et al., "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes", The Journal of Immunology, 1994, 153:5586-5592	
	43	TAKADA, Y. et al., "Molecular Cloning and Expression of the cDNA for alpha3 Subunit of Human alpha3beta1 (VLA-3), an Integrin Receptor for Fibronectin, Laminin, and Collagen", The Journal of Cell Biology, October 1991, 115(1):257-266	
	44	TUTING, T. et al., "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the TH1-Biasing Cytokines IL-12 and IFN-alpha", The Journal of Immunology, 1998, 160:1139-1147	
	45	VELCULESCU, V. et al., "Serial Analysis of Gene Expression", Science, October 1995, 270:484-487	
	46	VERES, G. et al., "The Molecular Basis of the Sparse Fur Mouse Mutation", Science, July 1987, 415-417	
✓	47	WAN, Y. et al., "Dendritic Cells Transduced with an Adenoviral Vector Encoding a Model Tumor-Associated Antigen for Tumor Vaccination", Human Gene Therapy, July 1997, 8:1355-1363	

Examiner Signature	<i>Karen A. Gamella</i>	Date Considered	9/3/03
--------------------	-------------------------	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUN 18 2002

RECEIVED